Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis ; year:2020
Thrombosis and haemostasis ; (2020)
- Contributor
-
Cohen, Alexander
Keshishian, Allison
Lee, Theodore
Wygant, Gail
Rosenblatt, Lisa
Hlavacek, Patrick
Mardekian, Jack
Wiederkehr, Daniel
Sah, Janvi
Luo, Xuemei
- DOI
-
10.1055/s-0040-1718728
- URN
-
urn:nbn:de:101:1-2021012009554665582118
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cohen, Alexander
- Keshishian, Allison
- Lee, Theodore
- Wygant, Gail
- Rosenblatt, Lisa
- Hlavacek, Patrick
- Mardekian, Jack
- Wiederkehr, Daniel
- Sah, Janvi
- Luo, Xuemei
Other Objects (12)
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Heparin and Venous Thrombo-Embolism
Low-molecular-weight heparins in the treatment of venous thromboembolism
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Spontaneous Hematomas in COVID-19 Patients on Low-Molecular-Weight Heparin
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Heparin and Venous Thrombo-Embolism
Low-molecular-weight heparins in the treatment of venous thromboembolism
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Spontaneous Hematomas in COVID-19 Patients on Low-Molecular-Weight Heparin
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Heparin and Venous Thrombo-Embolism
Low-molecular-weight heparins in the treatment of venous thromboembolism
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Spontaneous Hematomas in COVID-19 Patients on Low-Molecular-Weight Heparin
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences